SuperworthUpstream Bio market cap UPB
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Oct 23, 2026
- $150.1M
- Highest close in our data
- $1.7B
- Jan 2026
Upstream Bio is worth $150.1M at the close on Oct 23, 2026, at $2.74 a share.
That is down 87% over the last year.
Its highest close in our data was $1.7B in Jan 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $150.1M | $150.1M | $1.7B | −91% |
| 2025 | $1.6B | $327.2M | $1.6B | +55% |
| 2024 | $1B | $868.8M | $1.4B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Upstream Bio's size, closest first, today.
| Company | Market cap |
|---|---|
| UPBUpstream Bio | $150.1M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Upstream Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.